Status:

WITHDRAWN

The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Renal Insufficiency

Eligibility:

MALE

18-75 years

Phase:

PHASE1

Brief Summary

The primary purpose of this study is to obtain a preliminary pharmacokinetic profile of MK-7145 2 mg immediate release (IR) following single-dose administration in male participants with moderate rena...

Eligibility Criteria

Inclusion

  • Body mass index (BMI) 18 to 35 kg/m\^2
  • Nonsmoker and/or have not used nicotine or nicotine-containing products
  • for at least 3 months prior to enrollment
  • Estimated glomerular filtration rate (eGFR) 30 to 60 mL/min/1.73 m\^2

Exclusion

  • History of stroke, chronic seizures, or major neurological disorder
  • Ongoing, clinically significant endocrine, gastrointestinal, cardiovascular,
  • hematological, hepatic, immunological, respiratory, or genitourinary abnormalities or diseases
  • Systolic blood pressure (SBP) ≤95 mmHg or \>160 mmHg, or diastolic blood
  • pressure (DBP) ≤45 mmHg or \>95 mmHg
  • History of neoplastic disease except for adequately treated non-melanomatous skin carcinoma
  • Unable to refrain from, or anticipates the use of, strong/moderate cytochrome P450 3A4 (CYP3A4) inhibitors
  • Consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages, wine, or distilled spirits per day
  • Consumes excessive amounts of caffeine, defined as greater than 6 servings of coffee, tea, cola, or other caffeinated beverages per day
  • Had major surgery or donated blood within 8 weeks prior to enrollment
  • Has participated in another investigational study within 4 weeks prior
  • History of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food
  • Currently a regular user of illicit drugs, or has a history of drug (including alcohol) abuse within approximately 6 months
  • Has active or has a history of nephrolithiasis
  • Has had a kidney removed or has a functioning renal transplant

Key Trial Info

Start Date :

August 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01832103

Start Date

August 1 2013

End Date

December 1 2013

Last Update

September 24 2013

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.